Key facts
- This page summarizes Paul Reider's Form 4 filing for Coherus BioSciences, Inc. (CHRS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jan 2025, 20:50.
Paul Reider - 03 Jan 2025 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- CHRS
- Reported as of
- 03 Jan 2025
- Net transaction value
- -$3,780
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2025, 20:50:18 UTC
- Prior SEC filing
- 17 Dec 2024
- Next SEC filing
- 22 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Paul Reider filed Form 4 for Coherus BioSciences, Inc. (CHRS) on 07 Jan 2025.
Change
- Previous filing in this sequence was filed on 17 Dec 2024.
- Current net transaction value: -$3,780.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CHRS
transaction
Common Stock
Tax liability
- Transaction value
- $3,780
- Shares
- -2,277
- Change %
- -2.6%
- Price
- $1.66
- Shares after
- 86,927
- Date
- 04 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CHRS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +160,000
- Change %
- Price
- $0.000000
- Shares after
- 160,000
- Date
- 03 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 160,000
- Exercise price
- $1.66
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.
Footnote F2
The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 3, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.